TALK

The investment case for TALK has been overwritten by the March 9, 2026 definitive Merger Agreement with Universal Health Services, under which each share converts into the right to receive $5.25 in cash. At $5.20, the stock trades roughly 1% below the deal price, meaning the market is pricing a high probability of close with only modest arb spread remaining. This is no longer a fundamentals story — it is a deal-completion story gated on HSR clearance, state healthcare-law waiting periods, and a shareholder vote (all explicitly cited in the 10-K).

That said, the underlying business that UHS is buying is genuinely improving and explains why the board accepted the bid rather than going hostile-defensive. Revenue grew 22.0% to $229M in FY2025, the company posted its second straight year of GAAP profitability ($7.79M net income, +578.8% YoY), operating income inflected to $3.15M (+170.1%), and Payor sessions scaled from 1.229M to 1.617M completed sessions — clear evidence the insurance-reimbursed channel is the durable growth engine. The balance sheet is conservative (liabilities/equity 0.15x, $37.4M cash, no meaningful debt), and the company bought back $17.2M of stock in FY2025, which partly explains the 51.3% cash drawdown.